Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NKGen Biotech, Inc. - Common Stock (NQ: NKGN )

0.1913 UNCHANGED
Last Price Updated: 4:00 PM EST, Mar 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NKGen Biotech, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented
From NKGen Biotech
Via GlobeNewswire
NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program
NKGen explores the use of troculeucel as a potential treatment option for post-stroke patients. 
From NKGen Biotech
Via GlobeNewswire
Wondering what's happening in today's pre-market session?
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
These stocks are the most active in today's session
Curious about the most active stocks on Friday? Find out which stocks are dominating the market action! 
Via Chartmill
Gapping stocks in Friday's session
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
These stocks are moving in today's pre-market session
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program
NKGen takes a meaningful step towards potential treatment for frontotemporal dementia (“FTD”) patients with limited treatment options. 
From NKGen Biotech
Via GlobeNewswire
NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer’s Disease with AdventHealth Orlando as First East Coast Site
From NKGen Biotech
Via GlobeNewswire
Top movers in Friday's pre-market session
Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Get insights into the top gainers and losers of Thursday's after-hours session.
The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
The trading volume of these stocks is deviating from the norm in today's session.
The trading volume of these stocks is deviating from the norm in today's session. 
Via Chartmill
Which stocks are moving on Thursday?
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Thursday's session: gap up and gap down stocks
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
Thursday's pre-market session: top gainers and losers
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer’s Disease
From NKGen Biotech
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why AppLovin Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Keep an eye on the top gainers and losers in Wednesday's session.
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements. 
Via Chartmill
Traders are paying attention to the gapping stocks in Wednesday's session.
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
Wednesday's pre-market session: top gainers and losers
As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer’s Disease
From NKGen Biotech
Via GlobeNewswire
NKGen Biotech Selected as Stalking Horse Bidder for NKMax
From NKGen Biotech, Inc.
Via GlobeNewswire
NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel
From NKGen Biotech, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
From NKGen Biotech
Via GlobeNewswire
Why Spirit Airlines Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Dow Falls Over 100 Points; Netflix Posts Upbeat Results
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.